Rates of major bleeding with rivaroxaban in real-world studies of nonvalvular atrial fibrillation patients: a meta-analysis

Curr Med Res Opin. 2016 Jun;32(6):1117-20. doi: 10.1185/03007995.2016.1161610. Epub 2016 Mar 16.

Abstract

Numerous real-world studies estimating major bleeding rates in rivaroxaban patients with nonvalvular atrial fibrillation have been published. We performed a meta-analysis to better quantify the rates of different types of major bleeding seen with rivaroxaban in observational studies. The pooled rates of major bleeding with rivaroxaban were generally low and consistent with those reported in its pivotal randomized controlled trial.

Keywords: Major bleeding; Meta-analysis; Nonvalvular atrial fibrillation; Rivaroxaban.

Publication types

  • Meta-Analysis

MeSH terms

  • Anticoagulants / therapeutic use*
  • Atrial Fibrillation / complications
  • Atrial Fibrillation / drug therapy*
  • Hemorrhage / chemically induced
  • Hemorrhage / epidemiology*
  • Humans
  • Rivaroxaban / therapeutic use*
  • Stroke / drug therapy
  • Stroke / prevention & control
  • Treatment Outcome

Substances

  • Anticoagulants
  • Rivaroxaban